Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 392380 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
ElectronicAdd to Basket
Hard CopyAdd to Basket



The Outlook for Pharmaceuticals in Latin America to 2013
Espicom Business Intelligence Ltd, March 2008


  Description  
  Table of Contents  
  Summary  
  Countries Covered  
    
   
 Enquire before Buying  
 Send to a Friend  

The eight leading Latin American pharmaceutical markets are expected to grow by a CAGR of 9.9% between 2008 and 2013, outpacing the slowing North American markets. Each country report provides a comprehensive analysis of the pharmaceutical market, including five-year market forecasts. For each country you will receive 4 completely updated reports sent quarterly, plus a comprehensive report sent annually.

The pharmaceutical markets in Latin America are worth US$50 billion - and growing fast!

The eight Latin American markets covered represent a market of 474 million people with a GDP of US$3.4 trillion in 2008. The region is better prepared to face global instability than in the past but economic growth is expected to slow down in 2009 and 2010, after a recent period of remarkable growth. Access to medicines in the public sector has increased, particularly among the least well-off population, with initiatives such as Remediar in Argentina, PAC Saúde in Brazil, Auge in Chile, Seguro Popular in Mexico and Barrio Adentro in Venezuela. Governments are using their bargaining power to negotiate - and centralise - drug purchases in an effort to contain costs. At a regional level, MERCOSUR members have decided to establish a drug price database to compare and monitor drug prices. Overall, public drug expenditure in the region will continue to rise, as there is a considerable level of unfulfilled demand.

Private pharmacy sales are surging, as countries such as Brazil, Mexico and Venezuela have higher disposable incomes in a climate of macroeconomic stability. Innovative drug prices have risen, but governments have started to control them, either directly or indirectly. Contrary to what has happened in developed markets, generics consumption in Latin America is low, with the exception of Brazil. Local protectionism, very low prices and high production capabilities have helped the country to develop a sizeable bioequivalent generics market which has proved tough for foreign generics producers. In Mexico, Calderon’s government has started a renewal process for drug registrations, and it is expected that there will only be patented and bioequivalent generics by 2010. For the time being, however, Mexico remains on the 2008 USTR Watch List. The region is also facing a growing incidence of drug counterfeting, but initiatives are in place to control it.

Attractive opportunities remain in Latin America. The eight pharmaceutical markets covered by Espicom Business Intelligence will represent a value of US$80 billion at retail prices in 2013. With nearly twice the population of Mexico and a GDP of US$1.4 trillion, Brazil is the largest market. Economic stability and the depreciation of the US dollar are helping to bring private pharmacy sales to record figures in the country. Mexico is the second leading drug market, whilst Argentina and Venezuela each represent about a quarter and a third of the Brazilian and Mexican drug markets. Local producers are strengthening their manufacturing capabilities in order to maximise their export markets, particularly in other neighbouring Latin American countries. Combined domestic production represents about half of the regional market. Imports are valued at over US$10 billion but low exports contribute to a deficit in the pharmaceutical balance of trade of US$7 billion.

These reports analyse the issues

The Outlook for Pharmaceuticals in Latin America to 2013. Each report provides an individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually or as a discounted collection, and prices include 4 completely updated reports sent quarterly plus a comprehensive annual review.



Customers who bought this item also bought

The Pharmaceutical Market: Mexico

The Latin American Market for Generic Drugs - A Comparative Study of 7 Key Markets

Textile Outlook International - Business and Market Analysis for the Global Textile and Apparel Industries

The Pharmaceutical Market: Venezuela

The Market for Pharmaceuticals in Brazil, Russia, India & China 2008

E7: The Outlook for Pharmaceuticals to 2012

Analyzing the Global Pharmaceutical Industry

The Pharmaceutical Market: New Zealand



Top of page


   All rights reserved. � Copyright 2008 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds